Korean J Urol Oncol.  2016 Dec;14(3):109-117. 10.22465/kjuo.2016.14.3.109.

Recombinant Bacille Calmette–Guérin for Immunotherapy in Nonmuscle Invasive Bladder Cancer

Affiliations
  • 1Department of Urology, Chung-Ang University Hospital, Seoul, Korea. caucih@cau.ac.kr

Abstract

Intravesical instillation of Mycobacterium bovis bacille Calmette-Guérin (BCG) has been used for treating nonmuscle invasive bladder cancer as the forefront of immunotherapy, but BCG is ineffective in approximately 30-40% of cases and disease recurs in up to 50% of patients. Recently BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, and the genetic control of these mycobacteria is advanced in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. We will discuss current advances in recombinant BCG construction, research, and future directions.

Keyword

BCG vaccine; Urinary bladder neoplasms; Immunotherapy
Full Text Links
  • KJUO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr